Earlier this month, Stada proposed a slate of four new directors–but now, as promised, its rebel shareholder is out with an alternative lineup.
Monday, Active Ownership Capital revealed its own desired boardroom edits, which include ousting Chairman Martin Abend and Deputy Chairman Carl Ferdinand Oetker, Reuters reports. Active Ownership also isn’t too keen on Gunnar Riemann or Birgit Kudlek, two of Stada’s prospective appointments.
Instead, the proxy brawler–which holds about a 7% Stada stake–is asking its fellow investors to support the nomination of former Novartis compliance officer Eric Cornut; one-time Hexal CEO Hans-Helmut Fabry and CFO Klaus-Joachim Krauth; and Ursula Schuetze-Kreilkamp, who specializes in coaching leadership personnel. It’s fine with Stada’s other two nominees, Opel exec Tina Mueller and Amgen exec Rolf Hoffmann.
Tensions between the two sides have been brewing for a while now. After appearing to strike an accord back in May–under which Active Ownership would have replaced just three board members, instead of the 5 it initially wanted–Stada decided to go its own way, announcing it would make its own picks for replacement candidates.
Now, it’ll be up to shareholders to make a choice at the company’s annual meeting on Aug. 26. And the way Active Ownership sees it, it’s a crucial one–especially now that Stada’s directors may need to replace longtime chief Hartmut Retzlaff, who took a leave of absence for health reasons in early June.
“Should Mr. Retzlaff not return, it will surely be the task of the new supervisory board to overhaul the management board in a sensible fashion,” Active Ownership partner Florian Schuhbauer told the news service, noting that interim helmsman Matthias Wiedenfels doesn’t have the industry experience necessary to run the company.
Meanwhile, though, Wiedenfels has already begun doing just that, starting off with some more shuffling of Stada’s top ranks. Recently, Reuters reported that he’d stripped Retzlaff’s son, Steffen, of some of his duties and fired a group of external advisers.
By Carly Helfand
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
